AzurRx BioPharma, Inc. (NASDAQ: AZRX) Starts Presentation at the 2017 Marcum Microcap Conference
AzurRx BioPharma (NASDAQ: AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company's lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France. For more information, visit the company's website at www.azurrx.com About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and (3)…







